Skip to Main Content

Paper Details

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Nat Commun
73
2021
WHO grade IV glioblastoma, cancer, glioblastoma, glioblastoma tumors, glioblastomas, inflammatory gene signatures, patients, recurrent glioblastoma, tumor
Author NameAffiliation
Gao ZhangDuke University Medical Center
Gao ZhangThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Zhi WeiDepartment of Computer Science at the New Jersey Institute of Technology
Hai YanDuke University Medical Center
Hai YanThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Yiping HeThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Yiping HeDuke University Medical Center
Roel G W Verhaak
Roel G W Verhaak
Henry S FriedmanDuke University Medical Center
Henry S FriedmanThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Eric S LippDuke University Medical Center
Eric S LippThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Roger E McLendonThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Roger E McLendonDuke University Medical Center
Henry S FriedmanDuke University Medical Center
Henry S FriedmanThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
  • 1 - 17

Datasets

Release 1.2